Tumor derived exosomes (TEX) are small extracellular vesicles (30-120
nm) present in all body fluids of cancer patients, with multiple roles în
cancer progression, including tumor-stroma interaction, metastazis and
drug resistance.
The clinical implementation of exosomes for cancer screening and disease response or relapse prediction demands new facile methods for serum detection and quantification of TEX. The main scope of this project is to create a nano- platform based on a new class of magnetoplasmonic nanoparticles capable to selectively detect, bind and isolate acute myeloid leukemia-derived exosomes from blood samples using aptamer mediated recognition of tumor specific antigens (CD 117) for the modern management of cancer in the era of personalized medicine.
